Premium
Successful imaging of human cancer with indium‐111‐labeled phospholipid vesicles
Author(s) -
Presant Cary A.,
Proffitt Richard T.,
Turner A. Franklin,
Williams Lawrence E.,
Winsor David,
Werner John L.,
Kennedy Peter,
Wiseman Charles,
Gala Kirit,
McKenna Robert J.,
Smith J. Douglas,
Bouzaglou S. Armand,
Callahan Richard A.,
Baldeschwieler John,
Crossley Roger J.
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880901)62:5<905::aid-cncr2820620509>3.0.co;2-3
Subject(s) - medicine , pathology , prostate , prostate cancer , nuclear medicine , lung , thyroid , lymph node , cancer , radiology
Twenty‐four patients with proven primary and/or metastatic cancer received single intravenous injections of phospholipid vesicles containing 0.5 mCi of Indium‐111. Gamma camera scintigraphy 1 to 72 hours later visualized tumors in 22 patients (92%), including carcinomas of breast, lung, colon, prostate, kidney, cervix, thyroid, and soft tissue sarcoma, lymphoma, and melanoma. Tumor sites that were identified included soft tissues, bone, lung, liver, lymph node, and spinal cord. There were only two false‐positive images in metastatic sites and four false‐negative images in metastatic sites. Overall sensitivity for tumors in 97 individual sites was 85%, whereas specificity was 96%. Unsuspected areas of malignancy were seen in the lumbar subdural space, pleura, liver, thyroid, and lung. Besides tumor accumulations, homogeneous uptake was observed in normal liver and spleen. Radiation doses to these two organs were 2.2 and 2.9 cGy/0.5 mCi In‐111, respectively. Whole body radiation dose was 0.3 cGy/0.5 mCi. The use of Indium‐111‐labeled vesicles permits a wide variety of human tumors in primary and metastatic sites to be imaged without toxicity and with radiation doses comparable to other radionuclide scanning techniques.